Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical study.

Sudaka A, Susini A, Lo Nigro C, Fischel JL, Toussan N, Formento P, Tonissi F, Lattanzio L, Russi E, Etienne-Grimaldi MC, Merlano M, Milano G.

Invest New Drugs. 2013 Feb;31(1):59-65. doi: 10.1007/s10637-012-9834-6. Epub 2012 Jun 20.

PMID:
22714791
2.

Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines.

Guérin O, Etienne-Grimaldi MC, Monteverde M, Sudaka A, Brunstein MC, Formento P, Lattanzio L, Maffi M, Tonissi F, Ortholan C, Pagès G, Fischel JL, Lo Nigro C, Merlano M, Milano G.

Urol Oncol. 2013 Nov;31(8):1567-75. doi: 10.1016/j.urolonc.2012.03.003. Epub 2012 May 17.

PMID:
22608542
3.

Antitumor activity of cetuximab associated with the taxotere-cisplatin-fluorouracil (TPF) combination on an orthotopic head and neck cancer model.

Bozec A, Sudaka A, Etienne-Grimaldi MC, Brunstein MC, Fischel JL, Milano G.

Oral Oncol. 2011 Oct;47(10):940-5. doi: 10.1016/j.oraloncology.2011.07.028. Epub 2011 Sep 8.

PMID:
21862388
4.

Combination of docetaxel and vandetanib in docetaxel-sensitive or resistant PC3 cell line.

Monteverde M, Tonissi F, Fischel JL, Etienne-Grimaldi MC, Milano G, Merlano M, Lo Nigro C.

Urol Oncol. 2013 Aug;31(6):776-86. doi: 10.1016/j.urolonc.2011.03.018. Epub 2011 Jul 27.

PMID:
21795074
5.

Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.

Chefrour M, Milano G, Formento P, Giacometti S, Denden A, Renée N, Iliadis A, Fischel JL, Ciccolini J.

Fundam Clin Pharmacol. 2012 Aug;26(4):530-7. doi: 10.1111/j.1472-8206.2011.00945.x. Epub 2011 May 30.

PMID:
21623901
6.

The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts.

Bozec A, Etienne-Grimaldi MC, Fischel JL, Sudaka A, Toussan N, Formento P, Milano G.

Oral Oncol. 2011 May;47(5):340-4. doi: 10.1016/j.oraloncology.2011.02.020. Epub 2011 Mar 21.

PMID:
21421338
7.

EGFR Targeting in Hormone-Refractory Prostate Cancer: Current Appraisal and Prospects for Treatment.

Guérin O, Fischel JL, Ferrero JM, Bozec A, Milano G.

Pharmaceuticals (Basel). 2010 Jul 19;3(7):2238-2247. Review.

8.

Erlotinib in combination with capecitabine (5'dFUR) in resistant pancreatic cancer cell lines.

Chefrour M, Fischel JL, Formento P, Giacometti S, Ferri-Dessens RM, Marouani H, Francoual M, Renée N, Mercier C, Milano G, Ciccolini J.

J Chemother. 2010 Apr;22(2):129-33.

PMID:
20435574
9.

Tapered dose versus constant drug exposure to anti-EGFR drugs on head-and-neck cancer xenografts. A comparison between cetuximab and gefitinib.

Bozec A, Formento P, Fischel JL, Etienne-Grimaldi MC, Milano G.

Oral Oncol. 2010 Mar;46(3):172-7. doi: 10.1016/j.oraloncology.2009.11.010. Epub 2010 Feb 13.

PMID:
20156700
10.

Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model.

Bozec A, Sudaka A, Toussan N, Fischel JL, Etienne-Grimaldi MC, Milano G.

Ann Oncol. 2009 Oct;20(10):1703-7. doi: 10.1093/annonc/mdp070. Epub 2009 Jun 19.

PMID:
19542251
11.

Emerging molecular targeted therapies in the treatment of head and neck cancer.

Bozec A, Peyrade F, Fischel JL, Milano G.

Expert Opin Emerg Drugs. 2009 Jun;14(2):299-310. doi: 10.1517/14728210902997947. Review.

PMID:
19519286
12.

Impact of erythropoietin on the effects of irradiation under hypoxia.

Lo Nigro C, Maffi M, Fischel JL, Monteverde M, Catarsi P, Tonissi F, Lattanzio L, Riba M, Etienne-Grimaldi MC, Formento P, Milano G, Merlano M.

J Cancer Res Clin Oncol. 2009 Nov;135(11):1615-23. doi: 10.1007/s00432-009-0609-1. Epub 2009 Jun 5.

PMID:
19499245
13.

Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition.

Bozec A, Gros FX, Penault-Llorca F, Formento P, Cayre A, Dental C, Etienne-Grimaldi MC, Fischel JL, Milano G.

Eur J Cancer. 2008 Sep;44(13):1922-30. doi: 10.1016/j.ejca.2008.07.013. Epub 2008 Aug 6.

PMID:
18691881
14.

Overexpression of cortactin in head and neck squamous cell carcinomas can be uncoupled from augmented EGF receptor expression.

Fantozzi I, Grall D, Cagnol S, Stanchi F, Sudaka A, Brunstein MC, Bozec A, Fischel JL, Milano G, Van Obberghen-Schilling E.

Acta Oncol. 2008;47(8):1502-12. doi: 10.1080/02841860802089801.

PMID:
18607838
15.

Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model.

Bozec A, Sudaka A, Fischel JL, Brunstein MC, Etienne-Grimaldi MC, Milano G.

Br J Cancer. 2008 Jul 8;99(1):93-9. doi: 10.1038/sj.bjc.6604429. Epub 2008 Jun 24.

16.

The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data.

Lo Nigro C, Maffi M, Fischel JL, Formento P, Milano G, Merlano M.

BJU Int. 2008 Aug 5;102(5):622-7. doi: 10.1111/j.1464-410X.2008.07706.x. Epub 2008 May 20.

17.

Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity.

Beauclair S, Formento P, Fischel JL, Lescaut W, Largillier R, Chamorey E, Hofman P, Ferrero JM, Pagès G, Milano G.

Ann Oncol. 2007 Aug;18(8):1335-41.

PMID:
17693647
18.

Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer.

Guérin O, Formento P, Lo Nigro C, Hofman P, Fischel JL, Etienne-Grimaldi MC, Merlano M, Ferrero JM, Milano G.

J Cancer Res Clin Oncol. 2008 Jan;134(1):51-7. Epub 2007 Jun 26.

PMID:
17593391
19.

EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.

Dassonville O, Bozec A, Fischel JL, Milano G.

Crit Rev Oncol Hematol. 2007 Apr;62(1):53-61. Epub 2007 Feb 26. Review.

PMID:
17324578
20.

Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126.

Bozec A, Lassalle S, Gugenheim J, Fischel JL, Formento P, Hofman P, Milano G.

Br J Cancer. 2006 Sep 18;95(6):722-8. Epub 2006 Aug 29.

21.

Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel-erlotinib and 5-fluoro-5'-deoxyuridine.

Fischel JL, Ciccolini J, Formento P, Ferrero JM, Milano G.

Anticancer Drugs. 2006 Aug;17(7):807-13.

PMID:
16926630
22.

Epidermal growth factor receptor/angiogenesis dual targeting: preclinical experience.

Bozec A, Fischel JL, Milano G.

Curr Opin Oncol. 2006 Jul;18(4):330-4. Review.

PMID:
16721126
23.

Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation.

Bozec A, Formento P, Ciccolini J, Fanciullino R, Padovani L, Murraciole X, Fischel JL, Milano G.

Mol Cancer Ther. 2005 Dec;4(12):1962-71.

24.

Gefitinib-trastuzumab combination on hormone-refractory prostate cancer xenograft.

Formento P, Hannoun-Levi JM, Gérard F, Mazeau C, Fischel JL, Etienne-Grimaldi MC, Gugenheim J, Milano G.

Eur J Cancer. 2005 Jul;41(10):1467-73.

PMID:
15919200
26.

Taxotere-5'-deoxy-5-fluorouridine combination on hormone-refractory human prostate cancer cells.

Fischel JL, Ferrero JM, Formento P, Ciccolini J, Renée N, Formento JL, Milano G.

Anticancer Drugs. 2005 Mar;16(3):309-16.

PMID:
15711183
27.

Dual HER 1-2 targeting of hormone-refractory prostate cancer by ZD1839 and trastuzumab.

Formento P, Hannoun-Levi JM, Fischel JL, Magné N, Etienne-Grimaldi MC, Milano G.

Eur J Cancer. 2004 Dec;40(18):2837-44.

PMID:
15571968
28.

Lack of contribution of dihydrofluorouracil and alpha-fluoro-beta-alanine to the cytotoxicity of 5'-deoxy-5-fluorouridine on human keratinocytes.

Fischel JL, Formento P, Ciccolini J, Etienne-Grimaldi MC, Milano G.

Anticancer Drugs. 2004 Nov;15(10):969-74.

PMID:
15514566
29.

Pharmacological background of EGFR targeting.

Castillo L, Etienne-Grimaldi MC, Fischel JL, Formento P, Magné N, Milano G.

Ann Oncol. 2004 Jul;15(7):1007-12. Review.

PMID:
15205192
30.

Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity.

Etienne MC, Ilc K, Formento JL, Laurent-Puig P, Formento P, Cheradame S, Fischel JL, Milano G.

Br J Cancer. 2004 Jan 26;90(2):526-34.

31.

ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine.

Magné N, Fischel JL, Dubreuil A, Formento P, Ciccolini J, Formento JL, Tiffon C, Renée N, Marchetti S, Etienne MC, Milano G.

Clin Cancer Res. 2003 Oct 15;9(13):4735-42.

32.

Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil.

Magné N, Fischel JL, Tiffon C, Formento P, Dubreuil A, Renée N, Formento JL, Francoual M, Ciccolini J, Etienne MC, Milano G.

Br J Cancer. 2003 Aug 4;89(3):585-92.

33.

Oxaliplatin-5-fluorouracil and ionizing radiation. Importance of the sequence and influence of p53 status.

Magné N, Fischel JL, Formento P, Etienne MC, Dubreuil A, Marcié S, Lagrange JL, Milano G.

Oncology. 2003;64(3):280-7.

PMID:
12697970
34.

Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa").

Magné N, Fischel JL, Dubreuil A, Formento P, Poupon MF, Laurent-Puig P, Milano G.

Br J Cancer. 2002 May 6;86(9):1518-23.

35.

Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity.

Fischel JL, Formento P, Ciccolini J, Rostagno P, Etienne MC, Catalin J, Milano G.

Br J Cancer. 2002 Apr 8;86(7):1162-8.

36.

Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer.

Magné N, Fischel JL, Dubreuil A, Formento P, Marcié S, Lagrange JL, Milano G.

Br J Cancer. 2002 Mar 4;86(5):819-27.

37.

Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells.

Bottero V, Busuttil V, Loubat A, Magné N, Fischel JL, Milano G, Peyron JF.

Cancer Res. 2001 Nov 1;61(21):7785-91.

38.

Impact of thymidine phosphorylase surexpression on fluoropyrimidine activity and on tumour angiogenesis.

Marchetti S, Chazal M, Dubreuil A, Fischel JL, Etienne MC, Milano G.

Br J Cancer. 2001 Aug 3;85(3):439-45.

39.

Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines.

Fischel JL, Rostagno P, Formento P, Dubreuil A, Etienne MC, Milano G.

Br J Cancer. 2001 Feb;84(4):579-85.

40.

Time-schedule dependency of S 16020, a new topoisomerase II inhibitor.

Soudon J, Milano G, Poullain MG, Fischel JL, Formento P, Berlion M, Giroux B.

Anticancer Drugs. 1999 Jul;10(6):597-604.

PMID:
10885908
41.

Modulation of 5-fluorouracil by 5-ethyl-2'-deoxyuridine on cell lines expressing different dihydropyrimidine dehydrogenase activities.

Katona C, Tímár F, Jeney A, Fischel JL, Milano G, Pandi E, Kralovánszky J.

Anticancer Drugs. 1999 Jul;10(6):561-7.

PMID:
10885904
42.

Variable intrinsic sensitivity of human tumor cell lines to raltitrexed (Tomudex) and folylpolyglutamate synthetase activity.

Chéradame S, Chazal M, Fischel JL, Formento P, Renée N, Milano G.

Anticancer Drugs. 1999 Jun;10(5):505-10.

PMID:
10477170
43.
44.

Combination of irinotecan (CPT11) and 5-fluorouracil with an analysis of cellular determinants of drug activity.

Pavillard V, Formento P, Rostagno P, Formento JL, Fischel JL, Francoual M, Etienne MC, Milano G.

Biochem Pharmacol. 1998 Nov 15;56(10):1315-22.

PMID:
9825730
45.
46.

Dual modulation of 5-fluorouracil cytotoxicity using folinic acid with a dihydropyrimidine dehydrogenase inhibitor.

Fischel JL, Formento P, Etienne MC, Spector T, Renée N, Milano G.

Biochem Pharmacol. 1997 Jun 1;53(11):1703-9.

PMID:
9264323
47.

Relevance of tumoral folylpolyglutamate synthetase and reduced folates for optimal 5-fluorouracil efficacy: experimental data.

Chéradame S, Etienne MC, Chazal M, Guillot T, Fischel JL, Formento P, Milano G.

Eur J Cancer. 1997 May;33(6):950-9.

PMID:
9291820
48.

Impact of different fluorouracil biochemical modulators on cellular dihydropyrimidine dehydrogenase.

Haaz MC, Fischel JL, Formento P, Renée N, Etienne MC, Milano G.

Cancer Chemother Pharmacol. 1996;38(1):52-8.

PMID:
8603452
49.

Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation.

Fischel JL, Etienne MC, Spector T, Formento P, Renée N, Milano G.

Clin Cancer Res. 1995 Sep;1(9):991-6.

50.

Cell growth inhibitory effects of caulerpenyne, a sesquiterpenoid from the marine algae Caulerpa taxifolia.

Fischel JL, Lemee R, Formento P, Caldani C, Moll JL, Pesando D, Meinesz A, Grelier P, Pietra P, Guerriero A, et al.

Anticancer Res. 1995 Sep-Oct;15(5B):2155-60.

PMID:
8572617

Supplemental Content

Loading ...
Support Center